 | Up a level |
Voci, Davide; Götschi, Andrea; Held, Ulrike; Bingisser, Roland; Colucci, Giuseppe; Duerschmied, Daniel; Fumagalli, Riccardo M; Gerber, Bernhard; Hasse, Barbara; Keller, Dagmar I; Konstantinides, Stavros V; Mach, François; Rampini, Silvana K; Righini, Marc; Robert-Ebadi, Helia; Rosemann, Thomas; Roth-Zetzsche, Stéphanie; Sebastian, Tim; Simon, Noemi R; Spirk, David; ... (2023). Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial. Thrombosis research, 221, pp. 157-163. Elsevier 10.1016/j.thromres.2022.10.021
Barco, Stefano; Voci, Davide; Held, Ulrike; Sebastian, Tim; Bingisser, Roland; Colucci, Giuseppe; Duerschmied, Daniel; Frenk, André; Gerber, Bernhard; Götschi, Andrea; Konstantinides, Stavros V; Mach, François; Robert-Ebadi, Helia; Rosemann, Thomas; Simon, Noemi R; Spechbach, Hervé; Spirk, David; Stortecky, Stefan; Vaisnora, Lukas; Righini, Marc; ... (2022). Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. Haematology, 9(8), e585-e593. Elsevier 10.1016/S2352-3026(22)00175-2
